Check for updates

OPEN ACCESS

EDITED BY Xintong Ge, Tianjin Medical University General Hospital, China

REVIEWED BY

Junli Zhao, Duke University, United States Yongxiang Wang, Shandong Provincial Hospital, China

*CORRESPONDENCE Kaiyuan Wang ⊠ kywang@tmu.edu.cn Zhiyun Wang ⊠ 13820585625@163.com

SPECIALTY SECTION This article was submitted to Neuroinflammation and Neuropathy, a section of the journal Frontiers in Aging Neuroscience

RECEIVED 17 December 2022 ACCEPTED 11 January 2023 PUBLISHED 26 January 2023

CITATION

Lin Y, Gong Z, Ma C, Wang Z and Wang K (2023) Relationship between glycemic control and cognitive impairment: A systematic review and meta-analysis. *Front. Aging Neurosci.* 15:1126183. doi: 10.3389/fnagi.2023.1126183

COPYRIGHT

© 2023 Lin, Gong, Ma, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Relationship between glycemic control and cognitive impairment: A systematic review and meta-analysis

Yufeng Lin¹, Zhongying Gong¹, Chunchao Ma¹, Zhiyun Wang^{1*} and Kaiyuan Wang^{2*}

¹Department of Neurology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China, ²Department of Anesthesiology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China

Background: Diabetes mellitus, or hyperglycemia, is an independent risk factor for cognitive impairment. Here we systematically analyzed whether glycemic control could improve cognitive impairment in patients with diabetes mellitus (DM), hyperglycemia, or insulin resistance.

Methods: Three databases (PubMed, EMBASE, and Cochrane Library) and ClinicalTrials. gov were searched for randomized controlled trials analyzing the relationship between glycemic control and cognitive function assessments, published from database inception to June 2022. Patients in experimental groups were treated with antidiabetic drugs, while control groups were treated with a placebo or alternative antidiabetic drugs. Data analysis was conducted using RevMan 5.3 and StataSE-64, and standardized mean difference (SMD) and 95% confidence intervals (CIs) were calculated.

Results: Thirteen studies comprising 19,314 participants were included. Analysis revealed that glycemic control significantly attenuated the degree of decline in cognitive function assessment scores (SMD = 0.15; 95% CI 0.05, 0.26; p < 0.00001), and funnel plots confirmed no publication bias. Seven studies used Mini-Mental State Examination as the primary cognitive function assessment, showing that glycemic control significantly delayed the degree of decline in cognitive function assessment scores (SMD = 0.18; 95% CI 0.03, 0.34; p = 0.02). Similar results were seen in two studies using the Montreal Cognitive Assessment scale, but without significant difference (SMD = 0.05; 95% CI-0.10, 0.21; p = 0.51). One study using Auditory Word Learning Test (AVLT) showed that glycemic control significantly delayed the decline in cognitive function assessment scores (SMD = 0.52; 95% CI 0.11,0.93; p = 0.01), and another used Wechsler Memory Scale Revised, showing similar results (SMD = 1.45; 95% CI 0.86, 2.04; p < 0.00001). Likewise, a study that used Modified Mini-Mental State scale showed that glycemic control significantly delayed the decline in cognitive function assessment scores (SMD = -0.10; 95% CI-0.16, -0.03; p = 0.005). Lastly, one study used AVLT subtests to show that glycemic control delayed the decline in cognitive function assessment scores, although not statistically significant (SMD = 0.09; 95% CI-0.53, 0.71; p = 0.78).

Conclusion: Glycemic control through antidiabetic treatment correlates with the improvement of cognitive impairment in patients with DM, hyperglycemia or insulin resistance. However, further studies are needed to validate the results of this study.

Systematic Review Registration: PROSPERO, identifier CRD42022342260.

KEYWORDS

diabetes mellitus, hyperglycemia, antidiabetic drugs, cognitive impairment, meta-analysis

1. Introduction

Hyperglycemic conditions, particularly diabetes mellitus (DM), are strongly associated with the incidence of cognitive impairment, including both mild cognitive impairment and dementia (Biessels and Despa, 2018; van Sloten et al., 2020). Chronic peripheral hyperinsulinemia and insulin resistance are the main features of DM, but hyperglycemia is increasingly thought to be the cause of cognitive impairment in elderly patients with DM (Umegaki et al., 2017; Tahmi et al., 2021). Several studies have shown that patients with Alzheimer's disease (AD) have desensitized insulin signals in their brains, even in the absence of DM (Jash et al., 2020). Extensive abnormalities in insulin and insulin-like growth factor type I and II (IGF-I and IGF-II) signaling pathways in the brains of patients with AD suggest that AD may partially share characteristics with a neuroendocrine disease similar to DM (Xu et al., 2015). Chronic peripheral hyperinsulinemia can cause brain insulin resistance and defective insulin receptor activity by impairing the blood-brain barrier and insulin transport to the brain (He et al., 2020; Milstein and Ferris, 2021). Therefore, impaired brain insulin signaling may be one of the mechanisms underlying neurodegenerative disease that causes progressive impairment of learning, memory, and cognitive functions.

A previous randomized controlled trial has reported that patients with diabetes have worse cognitive performance than patients without diabetes; however, whether the incidence of dementia or cognitive impairment in patients with DM could benefit from glycemic control remains controversial (Moore et al., 2013; Biessels et al., 2021). The aim of this meta-analysis was therefore to investigate whether glycemic control in patients with DM or hyperglycemia can delay the degree of decline according to cognitive function assessment scores.

2. Materials and methods

2.1. For protocol registration

This systematic review was registered on the PROSPERO International prospective register of systematic reviews (CRD42022342260).

2.2. Search methods

We searched four medical databases, PubMed, EMBASE, Cochrane Library, and the clinical registry ClinicalTrials.gov, for studies published from database inception to June 2022. Terms used as subject headings in the search strategy included cognitive impairment, dementia, blood glucose, hyperglycemia, antidiabetic drugs, insulin resistance, and randomized controlled trials. Please see the supplemental information for the complete search strategy. There were no restrictions on the language or country of publication.

2.3. Inclusion and exclusion criteria

Randomized controlled trials assessing changes in cognitive function in patients with DM, hyperglycemia, or insulin resistance treated with controls or antidiabetic drugs, and who underwent follow-up for at least 3 months with reported cognition scores were screened and finally enrolled. The experimental group was treated with antidiabetic drugs while the control group was treated with placebo or another active antidiabetic drug (Table 1).

Studies with incomplete information or where the full text was not available were excluded. For duplicate studies, the most recent publications were selected. We further excluded reviews, retrospective studies, case reports, animal studies, and unrelated studies.

2.4. Outcomes

The primary outcome indicators for the cognitive function assessment were the Mini-Mental State Examination (MMSE) scale, Montreal Cognitive Assessment (MoCA) scale, Modified Mini-Mental State (3MS) scale, Wechsler Memory Scale Revised (WMS-R), and Auditory Word Learning Test (AVLT). In addition, the digit symbol substitution test (DSST) was selected as a secondary outcome indicator.

2.5. Study selection and data extraction

The Endnote X9 software was used for literature management. Two researchers (Yufeng Lin and Kaiyuan Wang) searched and downloaded literature according to the search strategy, and deleted any duplicates. Any disagreements were resolved by discussion with a third researcher (Zhongying Gong). Two researchers (Yufeng Lin and Chunchao Ma) independently screened the articles while referencing the inclusion criteria, and a third researcher (Kaiyuan Wang) helped resolve any disagreement. Through reading of the study titles, abstracts, and full texts, the final selected literature was identified and the reasons for exclusion of other studies were recorded. Details such as the first author, study type, year of publication, sample size, sex, age, intervention, follow-up time, and cognitive function assessment method used were recorded for each study according to a pre-designed standardized information extraction form.

2.6. Risk of bias assessment of included studies

The methodological quality of the included literature was evaluated by two researchers (Yufeng Lin and Zhongying Gong) using the Revised Cochrane Risk of Bias tool (RoB 2.0; Lester-Coll et al., 2006). Specific evaluation components included randomization process, deviation from intended interventions, missing outcome data, measurement of outcomes, and selective reporting of outcomes. By reading the full text, the risk of bias for each domain was judged as high, low, or unclear. If all domains were of low risk, the overall risk of bias was considered low, if at

TABLE 1 The clinical characteristics of enrolled studies.

Study	Country	Trial design	Sample size	Age (Mean)		Interv	vention	Cognitive	Cognitive s	Follow-up	
					Female)	Ex	Con	assessment	Baseline	Endpoint	(Month)
Biessels et al. (2021)	Netherlands	Randomized, double-blind, active-controlled	Ex: 1618 Con: 1545	Ex: 64.4 Con: 64.4	Ex:1002/616 Con:958/587	Linaliptin	Glimepiride	MMSE	Ex: 28.5 Con: 28.5	Ex: 28.2 Con: 28.3	40
Cukierman-Yaffe et al. (2014)	40 countries	Multicentre randomized open- label	Ex: 1683 Con: 1709	Ex: 62.71 Con: 62.84	Ex:1066/617 Con:940/769	Insulin glargine	Standard care	MMSE	Ex: 27.93 Con: 27.88	Ex: 27.65 Con: 27.36	74
Cukierman-Yaffe et al. (2020)	24 countries	Randomized, double-blind, placebo-controlled	Ex: 4351 Con: 4245	Ex: 65.5 Con: 65.5	Ex:2306/2045 Con:2292/1953	Dulaglutide	Placebo	MoCA	Ex: 25 Con: 25	Ex: 24.54 Con: 24.47	24
Cummings et al. (2021)	13 countries	Randomized, double-blind, active-controlled	Ex: 64 Con: 80	Ex: 73 Con: 73.5	Ex:45/19 Con:53/27	Apabetalone	Placebo	MoCA	Ex: 24 Con: 24	Ex: 24.5 Con: 24.4	12
Furie et al. (2018)	United States	Randomized, double-blind, placebo- controlled	Ex: 1699 Con: 1699	Ex: 63.0 Con: 63.1	Ex: 1140/559 Con:1113/586	Pioglitazone	Placebo	3MS	Ex: 96 Con: 97	Ex: 95.9 Con: 96.7	60
Guo et al., 2014	China	Randomized, double-blind, active-controlled	Ex: 29 Con: 29	Ex: 54.7 Con: 53.3	Ex:17/12 Con:19/10	Metformin	Placebo	WMS-R	Ex: 78.6 Con: 77.7	Ex: 99.2 Con: 77.1	6
Hanyu et al. (2009)	Japan	Prospective randomized, open- controlled	Ex: 15 Con: 17	Ex: 56.3 Con: 55.9	Ex:7/8 Con:8/9	Pioglitazone	Placebo	MMSE	Ex: 22.2 Con: 22.4	Ex: 23.1 Con: 22.1	6
Köbe et al., 2017	Germany	Randomized, double-blind, interventional	Ex: 18 Con: 22	Ex: 65 Con: 69	Ex: 8/10 Con:11/11	Resveratrol	Placebo	AVLT subtests	Ex: 44.9 Con: 44.2	Ex: 43.0 Con: 41.9	6.5
Li et al. (2021)	China	Prospective parallel, open-label	Ex: 24 Con: 23	Ex: 55.0 Con: 59.5	Ex:14/10 Con:9/14	GLP-1	Oral antidiabetic drugs	MMSE	Ex: 27.92 Con: 27.39	Ex: 28.96 Con: 27.48	3
Isik et al. (2017)	Turkey	Prospective, observational	Ex: 104 Con: 101	Ex: 74.75 Con: 76.12	Ex:47/57 Con:35/66	Sitagliptin +M39	Placebo	MMSE	Ex: 23.48 Con: 23.12	Ex: 24.18 Con: 23.12	6
Sato et al. (2011)	Japan	Prospective randomized, open- controlled	Ex: 21 Con: 21	Ex: 77.4 Con: 77.6	Ex:11/10 Con:9/12	Pioglitazone	Placebo	MMSE	Ex: 22.1 Con: 21.9	Ex: 23.1 Con: 21.6	6
Plastino et al. (2010)	Italy	Prospective, open label, observational study	Ex: 55 Con: 49	Ex: 81.7 Con: 73.7	Ex:26/29 Con:23/26	insulin+oral antidiabetic medication	Oral antidiabetic medication	MMSE	Ex: 21.9 Con: 20.4	Ex: 21.7 Con: 19.8	6
Lin et al. (2018)	China	Randomized, double-blind, placebo-controlled	Ex: 48 Con: 46	Ex: 66.5 Con: 67.4	Ex:26/22 Con:27/19	Metformin	Acarbose	AVLT	Ex: 16.1 Con: 15.9	Ex: 17.9 Con: 15.6	12

least one domain was of high risk, the overall risk of bias was considered to be high, and if any domain showed unclear risk and there were no high risks present in any domain, the overall risk of bias was determined to be unclear. A third researcher (Chunchao Ma) convened discussions to resolve any disagreement that arose between the two reviewers.

2.7. Data synthesis and analysis

The RevMan v5.3 software provided by the Cochrane Collaboration was used to perform statistical analysis of the extracted data. For continuous data, the analysis applied the mean difference (MD) or standardized mean difference (SMD), calculated with 95% confidence intervals (CIs). Cochrane's X^2 and I^2 tests were used to assess heterogeneity. Considering that the different methods of cognitive function assessments used might impact the study results, we conducted subgroup analyzes based on the scoring methods and applied SMD and random effects models for the analysis. To ensure study integrity, we further used the STATA-64 software for sensitivity analysis, and funnel plot analysis was used to detect publication bias.

3. Results

3.1. Study selection

A total of 850 studies were retrieved using the search strategy, and 361 duplicate studies were excluded. After screening the retrieved titles and abstracts, 329 irrelevant studies, 89 review studies, 15 clinical study protocols, and 23 congress abstracts were excluded. The remaining 33 full-text studies were retained and evaluated for eligibility. Ten studies that did not meet the inclusion criteria, three studies with incomplete data, and seven studies that did not meet the outcome criteria were excluded. Finally, 13 relevant studies were included (Hanyu et al., 2009; Plastino et al., 2010; Sato et al., 2011; Cukierman-Yaffe et al., 2014, 2020; Guo et al., 2014; Isik et al., 2017; Köbe et al., 2017; Furie et al., 2018; Lin et al., 2018; Biessels et al., 2021; Cummings et al., 2021; Li et al., 2021). The specific literature screening process is shown in Figure 1.

3.2. Basic clinical characteristics

Information on the authors, time of publication, country, trial design, sample size, age, intervention modality, cognitive function assessment and scores at enrollment and follow-up are summarized and presented in Table 1.

3.3. Risk of bias assessment


In terms of risk of bias of individual study, seven studies were classified as low risk (Sato et al., 2011; Cukierman-Yaffe et al., 2014; Isik et al., 2017; Furie et al., 2018; Biessels et al., 2021; Cummings et al., 2021; Li et al., 2021), two studies were moderate risk (Hanyu et al., 2009; Köbe et al., 2017), and four studies were high risk (Plastino et al., 2010; Guo et al., 2014; Lin et al., 2018; Cukierman-Yaffe et al., 2020). Two of the studies (Guo et al., 2014; Lin et al., 2018) did not provide the complete method of allocation concealment (Figure 2A). In terms of the overall risk of bias, there was a low risk of other biases; unclear risks for random sequence generation, incomplete outcome data, and selective reporting; and high risks for allocation concealment, binding of participants and personnel, and binding of outcome assessment (Figure 2B).


3.4. Cognitive function assessments

Thirteen studies comprising 19,314 participants were included. Analysis revealed that glycemic control significantly attenuated the degree of decline in cognitive function assessment scores (SMD=0.15; 95% CI 0.05, 0.26; p < 0.00001; Figure 3).

3.4.1. Mini-mental state examination

Seven studies that included a total of 6,985 participants (Hanyu et al., 2009; Plastino et al., 2010; Sato et al., 2011; Cukierman-Yaffe et al., 2014; Isik et al., 2017; Biessels et al., 2021; Li et al., 2021) used MMSE to assess cognitive function. Meta-analysis of these studies was performed using a random effects model, which showed that glycemic control had





a significant effect on cognitive function improvement (SMD = 0.18; 95% CI 0.03, 0.34; p = 0.02); however, within-group heterogeneity was significant (p = 0.0002, I² = 77%; Figure 3). The ReVman software was subsequently used to further examine each study, and the Stata software was used to perform sensitivity analysis (Figure 4). The results indicated that the source of heterogeneity originated from mainly two studies (Cukierman-Yaffe et al., 2014; Biessels et al., 2021). After removing the two, meta-analysis was performed using a fixed response model with the five remaining studies comprising 430 participants, showing that glycemic control remained significant in improving cognitive function (SMD = 0.41; 95% CI 0.15, 0.67; p = 0.002). Within-group heterogeneity was within the normal limits (p = 0.19, I² = 35%; Figure 5).

3.4.2. Montreal cognitive assessment

Two studies (Cukierman-Yaffe et al., 2020; Cummings et al., 2021) with 8,740 participants used MoCA to assess cognitive function. A meta-analysis of these studies was performed using a random effects model, which showed that glycemic control improved cognitive function, but the results were not significant (SMD = 0.05; 95% CI-0.10, 0.21; p = 0.51). The within-group heterogeneity was within the normal range (p = 0.22, l^2 = 33%; Figure 5).

3.4.3. Auditory word learning test

One study (Lin et al., 2018) which included 94 participants used AVLT for cognitive function assessment. Meta-analysis using a random

effects model showed a significant improvement in cognitive function by controlling blood glucose (SMD = 0.52; 95% CI 0.11, 0.93; p = 0.01; Figure 6). Meta-analysis using a random effects model of another study (Köbe et al., 2017) with 40 participants used AVLT subtests for cognitive function assessment and showed an improvement in cognitive function by controlling blood glucose, but without statistical significance (SMD = 0.09; 95% CI-0.53, 0.71, p = 0.78; Figure 5).

3.4.4. Wechsler memory scale revised

One study (Guo et al., 2014) included 57 participants and used WMS-R for cognitive function assessment. Meta-analysis using a random effects model showed a significant improvement in cognitive function by controlling blood glucose (SMD = 1.45; 95% CI 0.86, 2.04; p < 0.00001; Figure 5).

3.4.5. Modified mini-mental state

One study (Furie et al., 2018) with 3,398 participants used 3MS for cognitive function assessment. Meta-analysis of this study using a random-effects model showed a significant effect of controlling blood glucose on improvement in cognitive function (SMD = -0.10; 95% CI-0.16, -0.03; p = 0.005; Figure 5).

3.4.6. Digit symbol substitution test

Two studies (Cukierman-Yaffe et al., 2014, 2020) including 11,966 participants used DSST for secondary assessment of cognitive function.

L1.1 MMSE Biessels et al., 2021 28.2 2.1 1618 28.3 2.2 1545 15.8% -0.05 [-0.12, 0.02] Cukierman-Yaffe et al., 2014 27.65 2.73 1683 27.36 2.84 1709 15.9% 0.10 [0.04, 0.17] Hanyu et al., 2009 23.1 3.9 15 22.1 2.6 17 2.0% 0.30 [-0.40, 1.00] Sik et al., 2017 24.18 5.02 104 23.12 5.38 101 7.8% 0.20 [-0.07, 0.48] Li et al., 2021 28.96 1 24 27.48 1.72 23 2.5% 1.04 [0.43, 1.65] Plastino et al., 2010 21.7 4.1 55 19.8 5.1 49 5.1% 0.41 [-0.20, 1.02] Stabet al., 2011 23.1 4.1 21.6 3 21 2.5% 0.41 [-0.20, 1.02]			rimen		-	ontrol			Std. Mean Difference	Std. Mean Difference
Bisester al., 2021 28.2 2.1 1618 28.3 2.2 1545 15.8% -0.05[0.12, 0.02] bisester al., 2014 27.65 2.73 1683 27.3 6 2.44 1709 15.9% 0.30 [0.04, 0, 1.01] bisester al., 2017 24.19 5.02 104 23.12 5.8 101 7.8% 0.20 [-0.07, 0.48] bisester al., 2017 24.19 5.02 104 23.12 5.8 101 7.8% 0.20 [-0.07, 0.48] bisester al., 2010 21.7 4.1 55 19.8 5.1 49 5.1 % 0.41 [0.02, 0.80] bisester al., 2010 21.7 4.1 55 19.8 5.1 49 5.1 % 0.41 [0.02, 0.80] bistotal (195% C) 3520 24.54 4.53 4351 24.47 4.73 4245 16.5% 0.02 [-0.03, 0.06] bistotal (195% C) 441 5 42.2 0.0002); I* 77% Test for overall effect $Z = 2.00$ ($P = 0.0002$); I* 77% Test for overall effect $Z = 2.05$ 64 24.4 0.4 80 6.3% 0.22 [-0.11, 0.55] bistotal (195% C) 441 5 4225 22.9% 0.05 [-0.10, 0.21] telerogeneity: Tau* = 0.01; Ch* = 14.9, dr = 1 (P = 0.22); I* = 33% Test for overall effect $Z = 2.85$ ($P = 0.000$) 1.1.3 MoLT in et al., 2018 17.9 4.5 48 15.6 4.3 46 4.7% 0.52 [0.11, 0.53] bistotal (95% C) 48 46 4.7% 0.52 [0.11, 0.53] bistotal (95% C) 29 28 2.7% 1.45 [0.86, 2.04] telerogeneity: Not applicable Test for overall effect $Z = 2.82$ ($P = 0.000$) 1.1.4 WMS.R bistotal (95% C) 141 8 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] bistotal (95% C) 1609 15.9% -0.10 [-0.16, -0.03] bistotal (95% C) 18 22 ($P = 0.000$) 1.1.4 WINS.R bistotal (95% C) 18 2.2 ($P = 0.000$) 1.1.4 WINS.R bistotal (95% C) 18 2.2 ($P = 0.000$) 1.1.5 MS 1.1.6 MLT subtest Gove et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] 1.1.6 MLT subtest Gove et al., 2017 43 10.7 18 41.9 2.8 22 2.4% 0.09 [-0.53, 0.71] 1.1.6 MLT subtest Gove et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] 1.1.6 MLT subtest Gove et al., 2017 43 10.7 18 41.9 2.8 22 2.4% 0.09 [-0.53, 0.71] 1.1.6 MLT subtest Gove et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] 1.1.6 MLT subtest Gove et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] 1.1.6 MLT subtest Gove et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] 1.1.6 MLT subtest Gove et al., 2017 43 10.7 18	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Dublemma-Yaffe et al., 2014 27.65 2.73 1683 27.36 2.84 1709 15.9% 0.10 [0.04, 0.17] any et al., 2017 24.18 5.02 104 23.12 5.38 101 7.8% 0.30 [0.04, 0.00] sik et al., 2017 24.18 5.02 104 23.12 5.38 101 7.8% 0.20 [0.07, 0.48] 1 et al., 2021 28.06 1 24 27.48 1.72 23 2.5% 0.41 [0.20, 0.80] 3 bat et al., 2011 23.1 4.1 21 1.16 3 21 2.5 20 0.41 [0.20, 0.80] 3 bat et al., 2011 23.1 4.1 21 21.6 3 21 2.5% 0.41 [0.20, 0.80] 3 bat et al., 2011 23.1 4.1 21 21.6 3 21 2.5% 0.41 [0.20, 0.80] 3 bat et al., 2012 0.24 5.4 4.53 4351 24.47 4.73 4245 16.5% 0.22 [0.03, 0.06] 2 battoral effect Z = 2.30 (P = 0.02) 1.12 MoCA 2 battoral effect Z = 2.30 (P = 0.02) 1.2 MoCA 2 battoral effect Z = 0.50 (P = 0.01) 1.13 MAUT in et al., 2012 0.1 Ch ² = 1.49, df = 1 (P = 0.22); P = 33% Test for overall effect Z = 0.50 (P = 0.01) 1.14 MMS-R 3 battoral (95% C) 48 15.5 4.3 46 4.7% 0.52 [0.11, 0.53] 48 46 4.7% 0.52 [0.11, 0.53] 48 46 4.7% 0.52 [0.11, 0.53] 48 46 4.7% 0.52 [0.11, 0.53] 49 battoral (95% C) 29 21 8.5 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] 50 battoral (95% C) 29 21 8.5 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] 50 battoral (95% C) 29 21 8.5 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] 50 battoral (95% C) 29 21 8.5 29 77.8 1699 15.9% -0.10 [0.16, -0.03] 50 battoral (95% C) 50 8.7 1699 96.7 7.8 1699 15.9% -0.10 [0.16, -0.03] 50 battoral (95% C) 50 8.7 1699 96.7 7.8 1699 15.9% -0.10 [0.16, -0.03] 50 battoral (95% C) 169 169 1699 1699 15.9% -0.10 [0.16, -0.03] 50 battoral (95% C) 169 169 1699 1699 15.9% -0.10 [0.16, -0.03] 50 battoral (95% C) 169 169 1699 1699 15.9% -0.10 [0.16, -0.03] 50 battoral effect Z = 2.8 (P = 0.005) 51.6 AVLT subtests Characteristic or overall effect Z = 2.8 (P = 0.005) 51.6 AVLT subtests Characteristic or overall effect Z = 0.8 (Q) = 0.005 12 - (Q < 0.00001); P = 83% 52 2 2 4% 0.09 [0.53, 0.71] 52 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4 - 2 0 0 4										
Hany et al., 2009 231 33 35 15 22.1 2.6 17 2.0% 0.30 [0.01, 1.00] site et al., 2017 24.18 5.02 10.47 212 5.38 101 7.8% 0.20 [0.07, 0.48] Let al., 2011 23.1 4.1 21 21.6 3 21 2.5% 0.41 [0.20, 0.80] Sato et al., 201 21.7 4.1 65 19.8 5.1 49 5.1% 0.41 [0.20, 0.80] Sato et al., 201 21.7 4.1 6.7 19.8 21.2 5.3% 0.41 [0.20, 0.80] Sato et al., 201 21.7 4.1 6.7 19.8 21.2 5.3% 0.41 [0.20, 0.80] Sato et al., 201 22.5 $L^{p} = 28.16$, $df = 6 (P = 0.002)$; $P = 77\%$ Feet for overall effect. $Z = 2.80 (P = 0.02)$ L1.2 MoCA Underman-Yaffe et al., 2020 24.54 4.53 4351 24.47 4.73 4245 16.5% 0.02 [-0.03, 0.06] Cummings et al., 2021 24.5 0.5 64 24.4 0.4 80 6.3% 0.22 [-0.11, 0.55] Subtotal (95% C) 44.15 4322 52.9% 0.05 [-0.10, 0.21] Heterogeneity. Tau" = 0.01; ChF = 1.49, df = 1 (P = 0.22); P = 33% Test for overall effect. $Z = 0.86 (P = 0.000)$ L1.3 AVLT In et al., 2018 17.9 4.5 48 15.6 4.3 46 4.7% 0.52 [0.11, 0.93] Heterogeneity. Not applicable Test for overall effect. $Z = 2.47 (P = 0.01)$ L1.4 WMS.R Subtotal (95% C) 29 28 2.7% 1.45 [0.86, 2.04] Heterogeneity. Not applicable Test for overall effect. $Z = 2.82 (P = 0.000)$ L1.4 WMS.R Subtotal (95% C) 59 8.7 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Heterogeneity. Not applicable Test for overall effect. $Z = 2.82 (P = 0.005)$ L1.4 UNAS R Subtotal (95% C) 143 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Not applicable Test for overall effect. $Z = 2.82 (P = 0.005)$ L1.4 AUX subtest Give et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Diverted (25% C) 159 95.8.7 1699 95.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Heterogeneity. Not applicable Test for overall effect. $Z = 2.82 (P = 0.005)$ L1.6 AUX subtest Give et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Diverted (25% C) 159 50.7 18 2.2 (P = 0.005) L1.6 AUX subtest Give et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Diverted (25% C) 50 51 51 50 51 51 50 51 51 50 51 51 51 50 51 51 51 50 51 51 51 51 51 51 51 51 51 51 51 51 51							1545		-0.05 [-0.12, 0.02]	1
sik et al., 2017 24.18 5.02 104 23.12 5.38 101 7.8% 0.20 $[10.07, 0.48]$ tet al., 2021 28.06 1 24 27.48 1.72 23 2.5% 0.41 $[0.03, 0.31]$ Plastino et al., 2010 21.7 4.1 55 19.8 5.1 49 5.1% 0.41 $[0.02, 0.80]$ valuated 19% C) 350 C + 2.8.16, df = 6 (P = 0.0002); F = 77% test for overall effect Z = 2.30 (P = 0.002) L1.2 MoCA Unkerman-Yaffe et al., 2020 24.54 4.53 4351 24.47 4.73 4245 16.5% 0.02 $[1.0.3, 0.34]$ teterogeneity: Tau" = 0.02; Ch ² = 2.6.16, df = 6 (P = 0.0002); F = 77% test for overall effect Z = 0.56 (P = 0.51) L1.3 MLT In et al., 2012 24.54 4.53 4351 24.47 4.73 4245 16.5% 0.02 $[1.0.10, 0.52]$ teterogeneity: Tau" = 0.01; Ch ² = 4.44 0.48 0 6.3% 0.22 $[1.0.1, 0.55]$ Subtotal (95% C) 24.5 4.53 4351 24.47 4.73 4245 16.5% 0.02 $[1.0.10, 0.21]$ teterogeneity: Tau" = 0.01; Ch ² = 4.40, df = 1 (P = 0.22); F = 33% Test for overall effect Z = 0.65 (P = 0.51) L1.3 MLT In et al., 2018 17.9 4.5 48 15.6 4.3 46 4.7% 0.52 $[0.11, 0.93]$ Utitotal (95% C) 48 46 4.7% 0.52 $[0.11, 0.93]$ teterogeneity: Not applicable Test for overall effect Z = 2.47 (P = 0.01) L1.4 VMNS.R Subtotal (95% C) 29 28 2.7% 1.45 $[0.86, 2.04]$ teterogeneity: Not applicable Test for overall effect Z = 2.48 (P = 0.00001) L1.5 SINS Unite et al., 2014 99.2 18.5 29 77.1 10.3 28 2.7% 0.010 $[-0.16, -0.03]$ teterogeneity: Not applicable Test for overall effect Z = 2.82 (P = 0.0005) L1.6 AUL subtosets Subtotal (95% C) 1699 96.7 7.8 1699 15.9% -0.10 $[-0.16, -0.03]$ teterogeneity: Not applicable Test for overall effect Z = 2.82 (P = 0.005) L1.6 AUL subtosets Subtotal (95% C) 1699 96.7 7.8 1699 15.9% 0.015 $[0.05, 0.26]$ teterogeneity: Not applicable Test for overall effect Z = 0.202 (P = 0.703) Total (95% C) 18 22 2.4% 0.09 $[-0.53, 0.71]$ teterogeneity: Not applicable Test for overall effect Z = 0.0023 Test for overall effect Z = 0.003 Test for overall effect Z = 0.004) Test for overall effect Z = 0	•								• • •	r
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Hanyu et al., 2009	23.1	3.9	15	22.1	2.6	17	2.0%	0.30 [-0.40, 1.00]	
Plastino tal., 2010 21.7 4.1 55 188 5.1 49 51.8 0.41 $[0.02, 0.80]$ Sato tal., 2011 23.1 4.1 21 21.6 3 21 2.5 % 0.41 $[0.02, 0.80]$ Sato tal., 2011 23.1 4.1 21 21.6 3 21 2.5 % 0.41 $[0.02, 0.80]$ Heterogeneity. Tau" = 0.02; Chi" = 26.16, df = 6 (P = 0.0002); P = 77% statistical (95% C) 24.54 4.53 4351 24.47 4.73 4245 16.5 % 0.02 $[-0.03, 0.06]$ Jummings et al., 2021 24.54 4.53 4351 24.47 4.73 4245 16.5 % 0.22 $[-0.03, 0.06]$ Jummings et al., 2021 24.5 0.5 6 4 24.4 0.8 0 6.3 % 0.22 $[-0.11, 0.55]$ Subtotal (95% C) 4415 4325 22.9 % 0.05 $[-0.10, 0.21]$ Heterogeneity. Tau" = 0.01; Chi" = 1.49, df = 1 (P = 0.22); P = 33% Test for overall effect Z = 0.65 (P = 0.51) L1.3 ANLT in et al., 2018 17.9 4.5 48 15.6 4.3 46 4.7 % 0.52 $[0.11, 0.93]$ Subtotal (95% C) 48 46 4.7 % 0.52 $[0.11, 0.93]$ Heterogeneity. Not applicable Test for overall effect Z = 2.47 (P = 0.01) L1.4 WMS-R Sub et al., 2014 99.2 18.5 29 77.1 10.3 28 2.7 % 1.45 $[0.86, 2.04]$ Heterogeneity. Not applicable Test for overall effect Z = 4.83 (P < 0.00001) L1.5 SMS Tuite et al., 2017 49 10.7 18 41.9 12.8 22 2.4 % 0.09 $[-0.53, 0.71]$ Heterogeneity. Not applicable Test for overall effect Z = 2.82 (P = 0.005) L1.6 AUL subtests Sobe et al., 2017 49 10.7 18 41.9 12.8 22 2.4 % 0.09 $[-0.53, 0.71]$ Heterogeneity. Not applicable Test for overall effect Z = 2.82 (P = 0.005) L1.6 AUL subtests Sobe et al., 2017 49 10.7 18 41.9 12.8 22 2.4 % 0.09 $[-0.53, 0.71]$ Heterogeneity. Not applicable Test for overall effect Z = 2.82 (P = 0.005) Total (95% C) 70 729 9585 100.0 % 0.15 $[0.05, 0.26]$ Test for overall effect Z = 0.02 (Chi" = 69.23, df = 12 (P < 0.00001); P = 83% Test for overall effect Z = 0.02; Chi" = 69.23, df = 12 (P < 0.00001); P = 83% Test for overall effect Z = 0.02; Chi" = 69.23, df = 12 (P < 0.00001); P = 83% Test for overall effect Z = 0.00 (P = 0.004); P = 83% Test for overall effect Z = 0.004; Chi" = 69.23, df = 12 (P < 0.00001); P = 83% Test for overall effect Z = 0.004; Chi" = 69.23, df = 12 (P < 0.00001); P = 83%	lsik et al., 2017	24.18	5.02	104	23.12	5.38	101	7.8%	0.20 [-0.07, 0.48]	<u>+</u>
Sale et al., 2011 23.1 4.1 21 21.6 3 21 2.5% 0.41 ($b.20, 1.02$) biblicital (95% CI) 23.2 Chi ^P = 26.16, df = 6 (P = 0.002); P = 77% Fest for overall effect Z = 2.30 (P = 0.02) 1.12 MOCA Subtrait (95% CI) 4.14 5 4.53 4.35 1 24.47 4.73 4245 16.5% 0.02 ($b.03, 0.06$] Subtrait (95% CI) 4.14 5 4.325 22.9% 0.05 ($b.0.18$ (0.05 ($b.0.10$) 1.13 AVLT in et al., 2018 17.9 4.5 48 15.6 4.3 46 4.7% 0.52 ($b.0.11, 0.93$] 4.14 5 4.325 22.9% 0.05 ($b.0.10, 0.21$] 4.15 4.325 22.9% 0.05 ($b.0.10, 0.21$] 4.16 4.7% 0.52 ($b.0.11, 0.93$] 4.15 4.2 29 28 2.7% 1.45 ($b.86, 2.04$] 5.00 et al., 2014 9.2 18.5 29 77.1 10.3 28 2.7% 1.45 ($b.86, 2.04$] 5.00 et al., 2014 9.2 18.5 29 77.1 10.3 28 2.7% 1.45 ($b.86, 2.04$] 5.00 et al., 2014 9.2 18.5 29 77.1 10.3 28 2.7% 1.45 ($b.86, 2.04$] 5.00 et al., 2014 9.2 18.5 29 77.1 10.3 28 2.7% 1.45 ($b.86, 2.04$] 4.15 5.00 et al., 2018 9.5 8.7 1699 96.7 7.8 1699 15.9% -0.10 ($b.16, -0.03$] 4.16 AUX subtests 5.00 et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 ($b.53, 0.71$] 4.16 AUX subtests 5.00 et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 ($b.53, 0.71$] 4.16 AUX subtests 5.00 et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 ($b.53, 0.71$] 4.16 AUX subtests 5.00 et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 ($b.53, 0.71$] 4.16 aux subtests 5.00 et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 ($b.53, 0.71$] 4.16 aux subtests 5.01 ($b.95, CL$) 7.29 5955 100.0% 5.16 ($b.05, 0.26$] 5.16 (b	Li et al., 2021	28.96	1	24	27.48	1.72	23	2.5%	1.04 [0.43, 1.65]	
Subtoal (95% C) 3520 3465 51.5% 0.18 [0.03, 0.34] Heterogeneity. Tau ² = 0.02; Chi ² = 28.18, df = 6 (P = 0.0002); P = 77% Heterogeneity. Tau ² = 0.02 1.1.2 MoCA Duklerman-Yaffe et al., 2020 24.54 4.53 4351 24.47 4.73 4245 16.5% 0.02 [-0.03, 0.06] Dummings et al., 2020 24.54 4.53 4351 24.47 4.73 4245 16.5% 0.02 [-0.03, 0.06] Dummings et al., 2020 24.50 6.6 42.44 0.80 6.63% 0.22 [-0.01, 0.55] Subtoal (95% C) 4415 4325 22.9% 0.05 [-0.10, 0.21] Heterogeneity. Tau ² = 0.01; Chi ² = 1.49, df = 1 (P = 0.22); P = 33% Heterogeneity. Tau ² = 0.05 (P = 0.51) 1.1.3 AVLT In et al., 2018 17.9 4.5 48 15.6 4.3 46 4.7% 0.52 [0.11, 0.93] Heterogeneity. Not applicable Test for overall effect. Z = 0.86 (P = 0.01) 1.1.4 WMS-R Subtoal (95% C) 29 28 2.7% 1.45 [0.86, 2.04] Heterogeneity. Not applicable Test for overall effect. Z = 2.43 (P = 0.001) 1.1.4 WMS-R Subtoal (95% C) 29 28 2.7% 1.45 [0.86, 2.04] Heterogeneity. Not applicable Test for overall effect. Z = 2.82 (P = 0.005) 1.1.5 3MS Write et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity. Not applicable Test for overall effect. Z = 2.82 (P = 0.005) 1.1.6 AVLT subtest Cobe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity. Not applicable Test for overall effect. Z = 0.28 (P = 0.005) 1.1.6 AVLT subtest Cobe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity. Not applicable Test for overall effect. Z = 0.28 (P = 0.005) 1.1.6 AVLT subtest Cobe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity. Not applicable Test for overall effect. Z = 0.28 (P = 0.004) 1.1.5 (Mot applicable Test for overall effect. Z = 2.82 (P = 0.0004) 1.1.6 (Mot applicable Test for overall effect. Z = 0.28 (P = 0.004) 1.1.6 (Mot applicable Test for overall effect. Z = 0.28 (P = 0.004) 1.1.6 (Mot applicable Test for overall effect. Z = 0.28 (P = 0.004) 1.1.6 (Mot applicable Test for overall effect. Z = 0.28 (P = 0.004) 1.1.6 (Mot applic	Plastino et al., 2010	21.7	4.1	55	19.8	5.1	49	5.1%	0.41 [0.02, 0.80]	
Heterogeneity, Tau"= 0.02; Chi"= 26.16, df = 6 (P = 0.0002); P = 77% Fest for overall effect Z = 2.30 (P = 0.02) 1.1.2 MoCA Subierroan-Yaffe et al., 2020 24.54 4.53 4351 24.47 4.73 4245 16.5% 0.02 [-0.03, 0.06] Subierroan-Yaffe et al., 2020 24.54 4.53 4351 24.47 4.73 4245 16.5% 0.02 [-0.03, 0.06] Subierroan-Yaffe et al., 2020 24.54 4.53 4351 24.47 4.73 4245 16.5% 0.02 [-0.03, 0.06] Subierroan-Yaffe et al., 2020 24.54 4.53 4351 24.47 4.73 4245 16.5% 0.02 [-0.03, 0.06] Subierroan-Yaffe et al., 2020 24.54 4.53 4351 24.47 4.73 4245 16.5% 0.02 [-0.03, 0.06] Heterogeneity, Tau"= 0.01; Chi"= 1.49, df = 1 (P = 0.22); P = 33% Test for overall effect Z = 0.48 (P = 0.51) 1.1.3 AVLT In et al., 2018 17.9 4.5 48 15.6 4.3 46 4.7% 0.52 [0.11, 0.93] Heterogeneity, Not applicable Test for overall effect Z = 2.47 (P = 0.01) 1.1.4 VMS.R Subitotal (95% Cl) 29 28 2.7% 1.45 [0.86, 2.04] Heterogeneity, Not applicable Test for overall effect Z = 2.47 (P = 0.0001) 1.1.5 MS Subitotal (95% Cl) 29 28 2.7% 1.45 [0.86, 2.04] Heterogeneity, Not applicable Test for overall effect Z = 2.82 (P = 0.00001) 1.1.5 MS Subitotal (95% Cl) 1699 15.9% -0.10 [-0.16, -0.03] Heterogeneity, Not applicable Test for overall effect Z = 2.82 (P = 0.0000) 1.1.6 AVLT subtests Subitotal (95% Cl) 18 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity, Not applicable Test for overall effect Z = 0.28 (P = 0.78) Total (95% CL) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity, Tau"= 0.02; Chi"= 69.23, df = 12 (P < 0.0001); P = 63% Tearours [eronomical Effect Z = 2.89 (P = 0.0004)] Heterogeneity, Tau"= 0.02; Chi"= 69.23, df = 12 (P < 0.0001); P = 63% Tearours [eronomical Effect Z = 2.89 (P = 0.0004)] Heterogeneity, Tau"= 0.02; Chi"= 69.23, df = 12 (P < 0.0001); P = 63% Tearours [eronomical Effect Z = 2.89 (P = 0.0004)] Heterogeneity, Tau"= 0.02; Chi"= 69.23, df = 12 (P < 0.0001); P = 63% Tearours [eronomical Effect Z = 2.89 (P = 0.0004)] Heterogeneity, Tau"= 0.02; Chi"= 69.23, df = 12 (P < 0.0004)] Heterogeneity, Tau"= 0.02; Chi"= 69.23, df	Sato et al., 2011	23.1	4.1		21.6	3			0.41 [-0.20, 1.02]	+
Test for overall effect $Z = 2.30 (P = 0.02)$ L1.2 MoCA Jukierman-Yaffe et al., 2020 24.54 4.53 4351 24.47 4.73 4245 16.5% 0.02 [-0.03, 0.06] Jummings et al., 2021 24.5 0.5 64 24.4 0.4 80 6.3% 0.22 [-0.11, 0.55] Juntotal (95% CI) 4415 4325 22.9% 0.05 [-0.10, 0.21] Heterogeneity: Tau ² = 0.01; Chi ² = 1.48, df = 1 (P = 0.22); P = 33% Test for overall effect $Z = 2.65 (P = 0.51)$ L1.3 AVLT In et al., 2018 17.9 4.5 48 15.6 4.3 46 4.7% 0.52 [0.11, 0.93] Juttotal (95% CI) 48 46 4.7% 0.52 [0.11, 0.93] Heterogeneity: Not applicable Test for overall effect $Z = 2.47 (P = 0.01)$ L1.4 WMS-R Sub et al., 2014 99.2 18.5 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] Heterogeneity: Not applicable Test for overall effect $Z = 2.483 (P < 0.00001)$ L1.5 3MS Turie et al., 2018 95.9 8.7 1899 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Subtotal (95% CI) 189 15.9% -0.10 [-0.16, -0.03] Subtotal (95% CI) 199 15.9% -0.10 [-0.16, -0.03] Heterogeneity: Not applicable Test for overall effect $Z = 2.82 (P = 0.05)$ L1.6 AVLT subtests Cobe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable Test for overall effect $Z = 2.89 (P = 0.025)$ L1.6 AVLT subtests Cobe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable Test for overall effect $Z = 2.89 (P = 0.025)$ Total (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Chi ² = 68.23, df = 12 (P < 0.00011); P = 83% Test for overall effect $Z = 2.89 (P = 0.004)$ Heterogeneity: Tau ² = 0.02; Chi ² = 68.23, df = 12 (P < 0.00011); P = 83% Test for overall effect $Z = 2.89 (P = 0.004)$	Subtotal (95% CI)			3520			3465	51.5%	0.18 [0.03, 0.34]	•
L1.2 MOCA Duklerman-Yaffe et al., 2020 24.54 4.53 4351 24.47 4.73 4245 16.5% 0.02 [-0.03, 0.06] Dummings et al., 2021 24.5 0.5 64 24.4 0.4 80 6.3% 0.22 [-0.03, 0.06] Dummings et al., 2021 24.5 0.5 64 24.4 0.4 80 6.3% 0.22 [-0.11, 0.55] Dubtotal (95% CI) 4415 4325 22.9% 0.05 [-0.10, 0.21] Heterogeneity: Tau ² = 0.01; Chi ² = 1.49, df = 1 (P = 0.22); P = 33% Test for overall effect $Z = 0.86 (P = 0.51)$ L1.3 AVLT In et al., 2018 17.9 4.5 48 15.5 4.3 46 4.7% 0.52 [0.11, 0.93] Heterogeneity: Not applicable Test for overall effect $Z = 2.47 (P = 0.01)$ L1.4 WMS-R Subtotal (95% CI) 29 28 2.7% 1.45 [0.86, 2.04] Heterogeneity: Not applicable Test for overall effect $Z = 2.47 (P = 0.00001)$ L1.4 WMS-R Subtotal (95% CI) 29 28 2.7% 1.45 [0.86, 2.04] Heterogeneity: Not applicable Test for overall effect $Z = 2.82 (P = 0.00001)$ L1.5 MS Write et al., 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Fest for overall effect $Z = 2.82 (P = 0.0005)$ L1.6 AVLT subtests Gobe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable Test for overall effect $Z = 2.82 (P = 0.025)$ L1.6 AVLT subtests Gobe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Test for overall effect $Z = 2.82 (P = 0.025)$ L1.6 AVLT subtests Gobe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Test for overall effect $Z = 2.82 (P = 0.78)$ Total (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Not applicable Test for overall effect $Z = 2.89 (P = 0.02)$ Total (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tota ² = 0.02; Chi ² = 68.23, df = 12 (P < 0.0001); P = 83% Test for overall effect $Z = 2.89 (P = 0.02)$	Heterogeneity: Tau ² = 0.02; Ch	i ² = 26.11	6, df =	6 (P = 0	0.0002)	² = 7	7%			
builterman-Yaffe et al., 2020 24.54 4.53 4361 24.47 4.73 4245 16.5% 0.02 [-0.3, 0.06] cummings et al., 2021 24.5 0.5 84 24.4 0.4 80 6.3% 0.22 [-0.11, 0.55] subtotal (95% CI) 4415 4325 22.3% 0.05 [-0.10, 0.21] Heterogeneity: Tau ² = 0.01; Ch ² = 1.49, df = 1 (P = 0.22); P = 33% Test for overall effect: $Z = 0.15$ Ch ² = 0.51) L1.3 AVLT I.net al., 2018 17.9 4.5 48 15.6 4.3 46 4.7% 0.52 [0.11, 0.93] subtotal (95% CI) 48 46 4.7% 0.52 [0.11, 0.93] subtotal (95% CI) 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] Heterogeneity: Not applicable Test for overall effect: $Z = 2.47$ (P = 0.01) L1.4 WMS.R Subtotal (95% CI) 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] Heterogeneity: Not applicable Test for overall effect: $Z = 4.83$ (P < 0.00001) L1.5 3MS Undie tal., 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Subtotal (95% CI) 699 1699 15.9% -0.10 [-0.16, -0.03] Heterogeneity: Not applicable Test for overall effect: $Z = 2.82$ (P = 0.005) L1.6 AVLT subtests Gobe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Fest for overall effect: $Z = 0.25$ (P = 0.78) Total (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Ch ² = 69.203 Total (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Ch ² = 69.203 Total (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Ch ² = 69.203 Total (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Ch ² = 69.203 Total (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Ch ² = 69.203 Total (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Ch ² = 69.203 Total (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Ch ² = 69.203 Total (95% CI) 73 73 73 73 73 73 73 73 73 73 73 73 73	Test for overall effect: Z = 2.30	(P = 0.02	2)							
Dummings et al., 2021 24.5 0.5 64 24.4 0.4 80 6.3% 0.22 [0.11, 0.55] Subtotal (95% C) 4415 4325 22.9% 0.05 [-0.10, 0.21] 4415 4325 22.9% 0.05 [-0.10, 0.21] 4415 0.05 [-0.10, 0.21] 4415 0.05 [-0.10, 0.21] 4416 0.22 [0.11, 0.93] Subtotal (95% C) 48 15.6 4.3 46 4.7% 0.52 [0.11, 0.93] Subtotal (95% C) 48 46 4.7% 0.52 [0.11, 0.93] Subtotal (95% C) 48 46 4.7% 0.52 [0.11, 0.93] Subtotal (95% C) 29 28 2.7% 1.45 [0.86, 2.04] 48 46 4.7% 0.52 [0.11, 0.93] Subtotal (95% C) 29 28 2.7% 1.45 [0.86, 2.04] 49 20 et al., 2014 99.2 18.5 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] 48 46 4.7% 0.52 [0.11, 0.93] Subtotal (95% C) 29 28 2.7% 1.45 [0.86, 2.04] 49 20 et al., 2014 99.2 18.5 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] 49 et ergogeneity. Not applicable Fest for overall effect Z = 4.83 (P < 0.00001) 1.1.5 3MS Subtotal (95% C) 1699 1699 15.9% -0.10 [-0.16, -0.03] Fieltergogeneity. Not applicable Fest for overall effect Z = 2.82 (P = 0.005) 1.1.6 AVLT subtests Gibe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% C) 18 22 2.4% 0.09 [-0.53, 0.71] 40 - 2 0 2 4 4 Fest for overall effect Z = 0.28 (P = 0.78) Total (95% C) 9729 9585 100.0% 0.15 [0.05, 0.26] 40 - 2 0 2 4 Feature Enversione IV: Not applicable Fest for overall effect Z = 2.89 (P = 0.078) Total (95% C) 9729 9585 100.0% 0.15 [0.05, 0.26] 40 - 2 0 2 4 40 - 2 0 2 2 4 50 - 2 0 - 2 0 2 2 4 50 - 2 0 - 2 0 - 2 0 - 2 0 - 2 0 - 2	1.1.2 MoCA									
Subtotal $(95\% Cl)$ 4415 4325 22.9% 0.05 $[-0.10, 0.21]$ Heterogeneity: Tau ² = 0.01; Ch ² = 1.49, df = 1 (P = 0.22); P = 33% Fest for overall effect Z = 0.65 (P = 0.51) I.1.3 AVLT In et al., 2018 17.9 4.5 48 15.6 4.3 46 4.7% 0.52 [0.11, 0.93] Subtotal (95% Cl) 48 46 4.7% 0.52 [0.11, 0.93] Heterogeneity: Not applicable Fest for overall effect Z = 2.47 (P = 0.01) I.1.4 WMS.R Sub et al., 2014 99.2 18.5 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] Heterogeneity: Not applicable Fest for overall effect Z = 4.83 (P < 0.00001) I.1.5 3MS Write et al., 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Write et al., 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Write et al., 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Write et al., 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Write et al., 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Write et al., 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Write et al., 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Write et al., 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Write et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% Cl) 18 22 2.4% 0.09 [-0.53, 0.71] Heterogeneily: Not applicable Fest for overall effect Z = 2.82 (P = 0.05) I.1.6 AVLT subtests Gibe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Heterogeneily: Not applicable Fest for overall effect Z = 0.23 (Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect Z = 2.89 (P = 0.078) Heterogeneily: Tau ² = 0.02; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect Z = 2.89 (P = 0.078) Heterogeneily: Tau ² = 0.02; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect Z = 2.89 (P = 0.078) Heterogeneily: Tau ² = 0.02; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect Z = 2.89 (P = 0.004) Heterogeneily: Tau ² = 0.02; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overal	Cukierman-Yaffe et al., 2020	24.54	4.53	4351	24.47	4.73	4245	16.5%	0.02 [-0.03, 0.06]	+
Subtotal (95% C) 4415 4325 22.9% 0.05 [$(-0.10, 0.21)$] Heterogeneity: Tau ² = 0.01; Ch ² = 1.49, df = 1 (P = 0.22); P = 33% Fest for overall effect Z = 0.65 (P = 0.51) I.1.3 AVLT In et al., 2018 17.9 4.5 48 15.6 4.3 46 4.7% 0.52 [0.11, 0.93] Subtotal (95% C) 48 46 4.7% 0.52 [0.11, 0.93] Heterogeneity: Not applicable Fest for overall effect Z = 2.47 (P = 0.01) I.1.4 WMS.R Sub et al., 2014 99.2 18.5 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] Heterogeneity: Not applicable Fest for overall effect Z = 4.83 (P < 0.00001) I.1.5 3MS Write et al., 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% -0.10 [$(-0.16, -0.03)$] Heterogeneity: Not applicable Fest for overall effect Z = 2.82 (P = 0.005) I.1.6 AVLT subtests Gibe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [$(-0.53, 0.71]$] Subtotal (95% C) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Not applicable Fest for overall effect Z = 0.23 (P = 0.78) For overall effect Z = 0.23 (P = 0.78) For overall effect Z = 2.82 (P = 0.078) For overall effect Z = 2.89 (P = 0.078) For overall effect	Cummings et al., 2021							6.3%	• • •	+
Heterogeneity: Tau ² = 0.01; Chi ² = 1.49, df = 1 (P = 0.22); P = 33% Test for overall effect. Z = 0.65 (P = 0.51) 1.1.3 AVLT in et al., 2018 1.1.3 aVLT 1.1.4 UMS-R Subtatal (95% Cl) 1.1.4 WMS-R Sub et al., 2014 1.1.4 UMS-R Sub et al., 2014 1.1.5 3MS Furie et al., 2018 1.1.5 3MS Subtatal (95% Cl) 1.1.5 2017 1.1.5 2018 1.1.5 2018 1.	Subtotal (95% CI)						4325			♦
Test for overall effect: $Z = 0.65$ (P = 0.51) 1.1.3 AVLT in etal, 2018 17.9 4.5 48 15.6 4.3 46 4.7% 0.52 [0.11, 0.93] Subtotal (95% CI) 48 46 4.7% 0.52 [0.11, 0.93] Heterogeneity. Not applicable Test for overall effect: $Z = 2.47$ (P = 0.01) 1.1.4 WMS-R Subtotal (95% CI) 29 28 2.7% 1.45 [0.86, 2.04] Heterogeneity. Not applicable Test for overall effect: $Z = 4.83$ (P < 0.00001) 1.1.5 3MS Turie etal, 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Subtotal (95% CI) 1699 15.9% -0.10 [-0.16, -0.03] Subtotal (95% CI) 1699 15.9% -0.10 [-0.16, -0.03] Heterogeneity. Not applicable Test for overall effect: $Z = 2.82$ (P = 0.005) 1.1.6 AVLT subtests Cibe etal, 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity. Not applicable Test for overall effect: $Z = 0.28$ (P = 0.78) Total (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity. Tau ² = 0.02; Chi ² = 69.23, df = 12 (P < 0.00001); I ² = 83% Test for overall effect: $Z = 2.89$ (P = 0.078) Total (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity. Tau ² = 0.02; Chi ² = 69.23, df = 12 (P < 0.00001); I ² = 83% Test for overall effect: $Z = 2.89$ (P = 0.004) Test for overall effect: $Z = 2.89$ (P = 0.001)	Heterogeneity: Tau ² = 0.01; Ch	i ² = 1.49.	df = 1	(P = 0.	22); l ² =	33%				
Lin et al., 2018 17.9 4.5 48 15.6 4.3 46 4.7% 0.52 [0.11, 0.93] Subtotal (95% CI) 48 46 4.7% 0.52 [0.11, 0.93] Test for overall effect $Z = 2.47$ (P = 0.01) L1.4 WMS-R Suo et al., 2014 99.2 18.5 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] Subtotal (95% CI) 29 28 2.7% 1.45 [0.86, 2.04] Heterogeneity: Not applicable Fest for overall effect $Z = 4.83$ (P < 0.00001) L1.5 3MS Subtotal (95% CI) 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Subtotal (95% CI) 1699 1699 15.9% -0.10 [-0.16, -0.03] Subtotal (95% CI) 1699 1699 15.9% -0.10 [-0.16, -0.03] Heterogeneity: Not applicable Fest for overall effect $Z = 2.82$ (P = 0.005) L1.6 AVLT subtests Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable Fest for overall effect: $Z = 0.28$ (P = 0.000) Fest for overall effect: $Z = 0.28$ (P = 0.000); P = 83% Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for ov	Test for overall effect: Z = 0.65	(P = 0.51)	•						
Lin et al., 2018 17.9 4.5 48 15.6 4.3 46 4.7% 0.52 [0.11, 0.93] Subtotal (95% CI) 48 46 4.7% 0.52 [0.11, 0.93] Test for overall effect $Z = 2.47$ (P = 0.01) L1.4 WMS-R Suo et al., 2014 99.2 18.5 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] Subtotal (95% CI) 29 28 2.7% 1.45 [0.86, 2.04] Heterogeneity: Not applicable Fest for overall effect $Z = 4.83$ (P < 0.00001) L1.5 3MS Subtotal (95% CI) 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Subtotal (95% CI) 1699 1699 15.9% -0.10 [-0.16, -0.03] Subtotal (95% CI) 1699 1699 15.9% -0.10 [-0.16, -0.03] Heterogeneity: Not applicable Fest for overall effect $Z = 2.82$ (P = 0.005) L1.6 AVLT subtests Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable Fest for overall effect: $Z = 0.28$ (P = 0.000) Fest for overall effect: $Z = 0.28$ (P = 0.000); P = 83% Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for overall effect: $Z = 0.002$; Ch ² = 69.23, df = 12 (P < 0.00001); P = 83% Fest for ov	1 1 3 AV/I T									
Subtotal (95% CI) 48 46 4.7% 0.52 [0.11, 0.93] Heterogeneity: Not applicable Frest for overall effect: $Z = 2.47$ (P = 0.01) H.1.4 WMS-R Subtotal (95% CI) 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] Heterogeneity: Not applicable Fest for overall effect: $Z = 4.83$ (P < 0.00001) H.1.5 3MS Subtotal (95% CI) 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Subtotal (95% CI) 1699 1699 15.9% -0.10 [-0.16, -0.03] Heterogeneity: Not applicable Fest for overall effect: $Z = 2.82$ (P = 0.005) H.1.6 AVLT subtests Cobe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable Fest for overall effect: $Z = 0.28$ (P = 0.78) For all effect: $Z = 0.28$ (P = 0.004) Heterogeneity: Tau ² = 0.02; Chi ² = 69.23, df = 12 (P < 0.00001); I ² = 83% Fest for overall effect: $Z = 2.89$ (P = 0.004) Heterogeneity: Tau ² = 0.02; Chi ² = 69.23, df = 12 (P < 0.00001); I ² = 83%		170	4.5	48	15.6	43	46	17%	0.52/0.11/0.031	
Heterogeneity: Not applicable Fest for overall effect: $Z = 2.47$ (P = 0.01) L1.4 WMS-R Sub et al., 2014 99.2 18.5 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] Sub total (95% Cl) 29 28 2.7% 1.45 [0.86, 2.04] Heterogeneity: Not applicable Fest for overall effect: $Z = 4.83$ (P < 0.00001) L1.5 3MS Sub total (95% Cl) 1699 16.99 15.9% -0.10 [-0.16, -0.03] Sub total (95% Cl) 1699 15.9% -0.10 [-0.16, -0.03] Heterogeneity: Not applicable Fest for overall effect: $Z = 2.82$ (P = 0.005) L1.6 AVLT subtests Gobe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Sub total (95% Cl) 18 22 2.4% 0.09 [-0.53, 0.71] Sub total (95% Cl) 18 22 2.4% 0.09 [-0.53, 0.71] Sub total (95% Cl) 18 22 2.4% 0.09 [-0.53, 0.71] Fest for overall effect: $Z = 0.28$ (P = 0.08) For overall effect: $Z = 0.28$ (P = 0.78) For overall effect: $Z = 0.02$; Chi ² = 69.23, df = 12 (P < 0.00001); I ² = 83% Fest for overall effect: $Z = 2.89$ (P = 0.004) Favours [examplicable Fest for overall effect: $Z = 2.89$ (P = 0.004) Favours [examplicable] Fest for overall effect: $Z = 0.02$; Chi ² = 69.23, df = 12 (P < 0.00001); I ² = 83% Fest for overall effect: $Z = 2.89$ (P = 0.004) Favours [examplicable] Favours [examplicable]		17.5	4.5		15.0	4.5				•
The state for overall effect: $\vec{Z} = 2.47$ ($P = 0.01$) L1.4 WMS-R Buo et al., 2014 99.2 18.5 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] Subtotal (95% Cl) 29 28 2.7% 1.45 [0.86, 2.04] Heterogeneity: Not applicable Frest for overall effect: $Z = 4.83$ ($P < 0.00001$) L1.5 3MS Furie et al., 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Subtotal (95% Cl) 1699 1699 15.9% -0.10 [-0.16, -0.03] Heterogeneity: Not applicable Fest for overall effect: $Z = 2.82$ ($P = 0.005$) L1.6 AVLT subtests Köbe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable Fest for overall effect: $Z = 0.28$ ($P = 0.78$) Fortal (95% Cl) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Chi ² = 69.23, df = 12 ($P < 0.00001$); $I^2 = 83\%$ Fest for overall effect: $Z = 2.89$ ($P = 0.004$) Features [expression and a second of the second o				40			40	4.7 /0	0.52 [0.11, 0.55]	•
Solution et al., 2014 99.2 18.5 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] Subtotal (95% CI) 29 28 2.7% 1.45 [0.86, 2.04] Heterogeneity: Not applicable Frest for overall effect: $Z = 4.83$ (P < 0.00001) I.1.5 3MS Subtotal (95% CI) 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Subtotal (95% CI) 1699 1699 15.9% -0.10 [-0.16, -0.03] Heterogeneity: Not applicable Frest for overall effect: $Z = 2.82$ (P = 0.005) I.1.6 AVLT subtests Göbe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable Frest for overall effect: $Z = 0.28$ (P = 0.78) Fost for overall effect: $Z = 0.28$ (P = 0.004) Fost for overall effect: $Z = 2.89$ (P = 0.004) Ferst for overall effect: $Z = 2.89$ (P = 0.004) Favours [control]		(P = 0.01)							
Solution et al., 2014 99.2 18.5 29 77.1 10.3 28 2.7% 1.45 [0.86, 2.04] Subtotal (95% CI) 29 28 2.7% 1.45 [0.86, 2.04] Heterogeneity: Not applicable Frest for overall effect: $Z = 4.83$ (P < 0.00001) I.1.5 3MS Subtotal (95% CI) 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Subtotal (95% CI) 1699 1699 15.9% -0.10 [-0.16, -0.03] Heterogeneity: Not applicable Frest for overall effect: $Z = 2.82$ (P = 0.005) I.1.6 AVLT subtests Göbe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable Frest for overall effect: $Z = 0.28$ (P = 0.78) Fost for overall effect: $Z = 0.28$ (P = 0.004) Fost for overall effect: $Z = 2.89$ (P = 0.004) Ferst for overall effect: $Z = 2.89$ (P = 0.004) Favours [control]	114 WMS.R									
Subtotal (95% CI) 29 28 2.7% 1.45 [0.86, 2.04] Heterogeneity: Not applicable Fest for overall effect: $Z = 4.83$ (P < 0.00001) I.1.5 3MS Furie et al., 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Subtotal (95% CI) 1699 1699 15.9% -0.10 [-0.16, -0.03] Heterogeneity: Not applicable Fest for overall effect: $Z = 2.82$ (P = 0.005) I.1.6 AVLT subtests Cobie tal., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable Fest for overall effect: $Z = 0.28$ (P = 0.78) Fotal (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Chi ² = 69.23, df = 12 (P < 0.00001); I ² = 83% Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 2.89$ (P = 0.004) Fest for overall effect: $Z = 2.89$ (P = 0.004)		99.2	19.5	20	77 1	10.3	28	2 7%	1 45 0 86 2 0 41	
$\begin{array}{c} \text{Heterogeneity: Not applicable} \\ \text{Fest for overall effect: } Z = 4.83 \ (P < 0.00001) \\ \text{I.1.5 3MS} \\ \text{Furie et al., 2018} & 95.9 & 8.7 & 1699 & 96.7 & 7.8 & 1699 & 15.9\% & -0.10 \ [-0.16, -0.03] \\ \text{Subtotal (95% CI)} & 1699 & 1699 & 15.9\% & -0.10 \ [-0.16, -0.03] \\ \text{Heterogeneity: Not applicable} \\ \text{Fest for overall effect: } Z = 2.82 \ (P = 0.005) \\ \text{I.1.6 AVLT subtests} \\ \text{Gobe et al., 2017} & 43 & 10.7 & 18 & 41.9 & 12.8 & 22 & 2.4\% & 0.09 \ [-0.53, 0.71] \\ \text{Subtotal (95% CI)} & 18 & 22 & 2.4\% & 0.09 \ [-0.53, 0.71] \\ \text{Fest for overall effect: } Z = 0.28 \ (P = 0.78) \\ \text{Fest for overall effect: } Z = 0.28 \ (P = 0.004) \\ \text{Fest for overall effect: } Z = 2.89 \ (P $		33.2	10.5			10.5				
The state of the overall effect: $\vec{Z} = 4.83 \ (P < 0.00001)$ 1.1.5 3MS Subtotal (95% CI) 1699 96.7 7.8 1699 15.9% -0.10 [-0.16, -0.03] Subtotal (95% CI) 1699 1699 15.9% -0.10 [-0.16, -0.03] Heterogeneity: Not applicable Test for overall effect: $\vec{Z} = 2.82 \ (P = 0.005)$ 1.1.6 AVLT subtests (öbe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable Test for overall effect: $\vec{Z} = 0.28 \ (P = 0.78)$ Total (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Chi ² = 69.23, df = 12 \ (P < 0.00001); I ² = 83% Test for overall effect: $\vec{Z} = 2.89 \ (P = 0.004)$				20			20	2	110 [0100, 2104]	•
Furie et al., 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% $-0.10 [-0.16, -0.03]$ Subtotal (95% CI) 1699 1699 15.9% $-0.10 [-0.16, -0.03]$ $-0.10 [-0.16, -0.03]$ Heterogeneity: Not applicable Fest for overall effect: $Z = 2.82$ (P = 0.005) $-0.10 [-0.16, -0.03]$ $-0.10 [-0.16, -0.03]$ Li.6 AVLT subtests Cobe et al., 2017 43 10.7 18 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] $-0.10 [-0.16, -0.03]$ Heterogeneity: Not applicable Test for overall effect: $Z = 0.28$ (P = 0.005) 18 22 2.4% 0.09 [-0.53, 0.71] Icetar (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] -4 -2 0 2 4 Icetar (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] -4 -2 0 2 4 Icetar (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] -4 -2 0 2 4 Icetar (95% CI) 9729 9585		(P < 0.00	0001)							
Furie et al., 2018 95.9 8.7 1699 96.7 7.8 1699 15.9% $-0.10 [-0.16, -0.03]$ Subtotal (95% CI) 1699 1699 15.9% $-0.10 [-0.16, -0.03]$ $-0.10 [-0.16, -0.03]$ Heterogeneity: Not applicable Fest for overall effect: $Z = 2.82$ (P = 0.005) $-0.10 [-0.16, -0.03]$ $-0.10 [-0.16, -0.03]$ Li.6 AVLT subtests Cobe et al., 2017 43 10.7 18 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] $-0.10 [-0.16, -0.03]$ Heterogeneity: Not applicable Test for overall effect: $Z = 0.28$ (P = 0.005) 18 22 2.4% 0.09 [-0.53, 0.71] Icetar (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] -4 -2 0 2 4 Icetar (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] -4 -2 0 2 4 Icetar (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] -4 -2 0 2 4 Icetar (95% CI) 9729 9585	1.1.5 3MS									
Subtotal (95% CI) 1699 1699 15.9% -0.10 [-0.16, -0.03] Heterogeneity: Not applicable Fest for overall effect: $Z = 2.82$ (P = 0.005) H.1.6 AVLT subtests Cobe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable Fest for overall effect: $Z = 0.28$ (P = 0.78) Fotal (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Chi ² = 69.23, df = 12 (P < 0.00001); I ² = 83% Fest for overall effect: $Z = 2.89$ (P = 0.004) Favours [control]		95.9	87	1699	967	78	1699	15.9%	-0.10[-0.16]-0.03	=
$\begin{array}{c} \text{Heterogeneity: Not applicable} \\ \text{Fest for overall effect: } Z = 2.82 \ (P = 0.005) \\ \textbf{I.1.6 AVLT subtests} \\ \text{(öbe et al., 2017 43 10.7 18 41.9 12.8 22 2.4\% 0.09 [-0.53, 0.71]} \\ \text{Subtotal (95\% CI) 18 22 2.4\% 0.09 [-0.53, 0.71]} \\ \text{Heterogeneity: Not applicable} \\ \text{Fest for overall effect: } Z = 0.28 \ (P = 0.78) \\ \text{Total (95\% CI) 9729 9585 100.0\% 0.15 [0.05, 0.26]} \\ \text{Heterogeneity: Tau2 = 0.02; Chi2 = 69.23, df = 12 \ (P < 0.00001); I2 = 83\% \\ \text{Fest for overall effect: } Z = 2.89 \ (P = 0.004) \\ \end{array}$		00.0	0.7		00.7	1.0				•
The state of the overall effect: $\vec{Z} = 2.82 (P = 0.005)$ 1.1.6 AVLT subtests (36be et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable Test for overall effect: $\vec{Z} = 0.28 (P = 0.78)$ Total (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Chi ² = 69.23, df = 12 (P < 0.00001); I ² = 83% Test for overall effect: $\vec{Z} = 2.89 (P = 0.004)$ Feature (experimental) Exposure (control)										
Köbe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable 0.09 [-0.53, 0.71] 0.09 [-0.53, 0.71] Fortal (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Chi ² = 69.23, df = 12 (P < 0.00001); l ² = 83% 0.15 [0.05, 0.26] -4 -2 0 2 4 Fest for overall effect: Z = 2.89 (P = 0.004) 9729 9585 100.0% 0.15 [0.05, 0.26] -4 -2 0 2 4		(P = 0.00)5)							
Köbe et al., 2017 43 10.7 18 41.9 12.8 22 2.4% 0.09 [-0.53, 0.71] Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable 0.09 [-0.53, 0.71] 0.09 [-0.53, 0.71] Fortal (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Chi ² = 69.23, df = 12 (P < 0.00001); l ² = 83% 0.15 [0.05, 0.26] -4 -2 0 2 4 Fest for overall effect: Z = 2.89 (P = 0.004) 9729 9585 100.0% 0.15 [0.05, 0.26] -4 -2 0 2 4	1 1 6 AVA T subtasts									
Subtotal (95% CI) 18 22 2.4% 0.09 [-0.53, 0.71] Heterogeneity: Not applicable Fest for overall effect: Z = 0.28 (P = 0.78) fotal (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Chi ² = 69.23, df = 12 (P < 0.00001); I ² = 83% 0.15 [0.05, 0.26] -4 Fest for overall effect: Z = 2.89 (P = 0.004) Eavours [control] Eavours [control]		43	107	10	41.0	120	22	2.404	0.001.052.0741	
Heterogeneity: Not applicable Fest for overall effect: Z = 0.28 (P = 0.78) Total (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Chi ² = 69.23, df = 12 (P < 0.00001); I ² = 83% 0.15 [0.05, 0.26] -4 -2 0 2 4 Fest for overall effect: Z = 2.89 (P = 0.004) Eavours [control] Eavours [control] Eavours [control]		43	10.7		41.9	12.8				-
Fest for overall effect: Z = 0.28 (P = 0.78) Fotal (95% CI) 9729 9585 100.0% 0.15 [0.05, 0.26] Heterogeneity: Tau ² = 0.02; Chi ² = 69.23, df = 12 (P < 0.00001); I ² = 83% 0.15 [0.05, 0.26] -4 -2 0 2 4 Fest for overall effect: Z = 2.89 (P = 0.004) Eavours (control) Eavours (control) Eavours (control)				10			22	2.470	0.09 [-0.00, 0.7 1]	Ŧ
Heterogeneity: Tau ² = 0.02; Chi ² = 69.23, df = 12 (P < 0.00001); l ² = 83% + <td< td=""><td></td><td>(P = 0.78</td><td>3)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>		(P = 0.78	3)							
Heterogeneity: Tau ² = 0.02; Chi ² = 69.23, df = 12 (P < 0.00001); l ² = 83% + <td< td=""><td>Total (95% CI)</td><td></td><td></td><td>9729</td><td></td><td></td><td>9585</td><td>100 በ%</td><td>0.15 [0.05, 0.26]</td><td>•</td></td<>	Total (95% CI)			9729			9585	100 በ%	0.15 [0.05, 0.26]	•
Fest for overall effect: Z = 2.89 (P = 0.004) Fest for overall effect: Z = 2.89 (P = 0.004) Favours (control)		ui² = 69.2°	3 df≓		0 0000	1) · 12 -			0.10 [0.00, 0.20]	· · · · · · · · · · · · · · · · · · ·
				12 (1 5	0.0000		5570			· · · · · · ·
				f = 5/P	< 0.00	1011	= 88 <i>4</i>	%		Favours [experimental] Favours [control]
	restres suburous uniciences.	- 4.	2.00.0	5 (0.000	5517.1	- 00.4	~		

Meta-analysis performed on these studies using a fixed effects model showed that glycemic control had a significant effect on increasing DSST scores (SMD = -0.80; 95% CI 0.77, 0.83, p < 0.00001; Figure 6).


3.5. Publication bias

For the seven studies in which MMSE was the primary assessment method of cognitive function, we performed publication bias analysis and subsequently created funnel plots. As shown in Figure 7, the left and right scatter points within the plot were largely symmetrical, and Egger's test further confirmed no publication bias (p = 0.076; see Figure 8).

4. Discussion

The incidence of hyperglycemia or DM and cognitive impairment both increase progressively with age. In a 10-year population-based cohort study of individuals aged 65 years and older, a modest degree of hyperglycemia was proven to independently predispose to faster cognitive decline, and glucose and hemoglobin A1c (HbA1c) were proposed as more sensitive markers of glycemia (Ganguli et al., 2020). Other studies have shown that the risk of developing cognitive decline or dementia in patients with type 2 DM is 1.25 to 2 times higher than that in patients without diabetes (Gudala et al., 2013; Xue et al., 2019). Morris et al. (2016) used the hyperinsulinemic-euglycemic clamp technique to detect systemic insulin resistance in patients with mild cognitive impairment (MCI) and AD as compared to normal controls, observing increased insulin resistance in 15 patients with cognitive impairment. Even in children with newly diagnosed type 1 DM, a single DKA episode was found to be associated with cognitive decline, particularly in subtle memory function (Ghetti et al., 2020). Although severe hypoglycemia may also lead to poor global cognition in older adults (Lacy et al., 2020), mounting clinical evidence has shown that cognitive impairment is exacerbated by hyperglycemia or DM in large populations.

The pathophysiological process of cognitive decline in patients with hyperglycemia or DM is complex and may involve common features with the pathogenesis of AD and vascular dementia (Gerstein et al., 2020), although the molecular interactions between the two diseases



are not fully understood. The physio-pathological mechanisms that characterize AD, including molecular, biochemical, and signaling abnormalities, are known to be similar to those of patients with diabetes. In addition, reduced insulin signaling in the brain due to insulin dysfunction may be the primary mechanism shared by both diseases (Duarte et al., 2012). The concept of "insulin-resistant brain state (IRBS)" has thus been proposed to better describe the nature of AD (de la Monte and Wands, 2008). Insulin resistance is associated with reduced cortical insulin receptor activation, impaired clearance of amyloid-ß (Aß) oligomers, increased cerebral abnormal neurotic plaque burden, and the cerebral microvascular dysfunction which is associated with memory loss or decline of cognition (Umegaki et al., 2017; van Sloten et al., 2020). Glucotoxicity from the accumulation of advanced glycation end products (AGEs) and their precursor methylglyoxal (MGO) could induce dopaminergic dysfunction, thereby playing a role in DM-associated cognitive impairment (Pignalosa et al., 2021).

In the present study, we reviewed and evaluated the potential protective effect of blood glucose control therapy on cognitive function in patients with DM, hyperglycemia, or insulin resistance. Thirteen trials with 19,134 participants were enrolled for preliminary outcome analysis. The MMSE, MoCA, AVLT, WMS-R, 3MS, and AVLT were used as primary cognitive function assessment methods. Overall analysis showed that glycemic control significantly attenuated cognitive decline. Several recent reviews and meta-analyzes have also investigated the relationship between antidiabetic therapy and cognitive status, with inconsistent primary findings (Areosa Sastre et al., 2017; Cao et al., 2018; McMillan et al., 2018). These inconsistencies are mainly due to differences in the focus and

detailed design of the studies. For example, Areosa Sastre's review only enrolled patients diagnosed with type 2 DM, while Cao's study enrolled patients diagnosed with Alzheimer's disease, but was not restricted to those with DM. In McMillan's review, only the incidence of dementia was analyzed, and the change in cognitive score which may compromise the potential cerebral protection of blood glucose control therapy was not evaluated (McMillan et al., 2018).

5. Limitations

The present review and analysis have several limitations which should be noted. First, the enrolled studies applied different cognitive function assessment methods, resulting in heterogeneity between groups. Second, the studies had various follow-up times, and longer follow-up periods would have allowed for more accurate detection of changes in cognitive function. Third, the optimal glycemic range for the prevention of cognitive decline could not be determined in this study, and thus further exploration through high-quality clinical trials is required.


6. Conclusion

In conclusion, the current study provides evidence that glycemic control could improve the cognitive impairment through cognitive function assessment scores in patients with DM, hyperglycemia or insulin resistance.

	Expe	rimen	tal	C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.1.1 MMSE									
Biessels et al., 2021	28.2	2.1	1618	28.3	2.2	1545	0.0%	-0.05 [-0.12, 0.02]	
Cukierman-Yaffe et al., 2014	27.65	2.73	1683	27.36	2.84	1709	0.0%	0.10 [0.04, 0.17]	
Hanyu et al., 2009	23.1	3.9	15	22.1	2.6	17	3.9%	0.30 [-0.40, 1.00]	_
sik et al., 2017	24.18	5.02	104	23.12	5.38	101	12.0%	0.20 [-0.07, 0.48]	
Li et al., 2021	28.96	1	24	27.48	1.72	23	4.8%	1.04 [0.43, 1.65]	
Plastino et al., 2010	21.7	4.1	55	19.8	5.1	49	8.7%	0.41 [0.02, 0.80]	
Sato et al., 2011	23.1	4.1	21	21.6	3	21	4.8%	0.41 [-0.20, 1.02]	
Subtotal (95% CI)			219			211	34.3%	0.41 [0.15, 0.67]	◆
Heterogeneity: Tau ² = 0.03; Cr Test for overall effect: Z = 3.10			(P = 0	.19); l² =	35%				
1.1.2 MoCA									
Cukierman-Yaffe et al., 2020	24.54	4.53	4351	24.47	4.73	4245	18.9%	0.02 [-0.03, 0.06]	+
Cummings et al., 2021	24.5	0.5	64	24.4		80	10.3%	0.22 [-0.11, 0.55]	
Subtotal (95% CI)			4415			4325	29.2%	0.05 [-0.10, 0.21]	•
Heterogeneity: Tau² = 0.01; Cr Test for overall effect: Z = 0.65			(P = 0	.22); l² =	33%				
1.1.3 AVLT									
_in et al., 2018	17.9	4.5	48	15.6	4.3	46	8.2%	0.52 [0.11, 0.93]	
Subtotal (95% CI)			48			46	8.2%	0.52 [0.11, 0.93]	◆
Heterogeneity: Not applicable									
Fest for overall effect: Z = 2.47	(P = 0.01)							
1.1.4 WMS-R									
Guo et al., 2014	99.2	18.5	29	77.1	10.3	28	5.1%	1.45 [0.86, 2.04]	
Subtotal (95% CI)			29			28	5.1%	1.45 [0.86, 2.04]	
Heterogeneity: Not applicable Test for overall effect: Z = 4.83	(P < 0.00	0001)							
1.1.5 3MS									
Furie et al., 2018	95.9	8.7	1699	96.7	7.8	1699	18.5%	-0.10 [-0.16, -0.03]	
Subtotal (95% CI)			1699			1699	18.5%	-0.10 [-0.16, -0.03]	9
Heterogeneity: Not applicable									
Fest for overall effect: Z = 2.82	(P = 0.00)5)							
1.1.6 AVLT subtests									
<öbe et al., 2017	43	10.7	18	41.9	12.8	22	4.7%	0.09 [-0.53, 0.71]	<u> </u>
Subtotal (95% CI)			18			22	4.7%	0.09 [-0.53, 0.71]	-
Heterogeneity: Not applicable									
Fest for overall effect: Z = 0.28	(P = 0.78	3)							
ſotal (95% CI)			6428			6331	100.0%	0.27 [0.12, 0.43]	◆
Heterogeneity: Tau ² = 0.03; Ch	i ² = 59.3	6.df=		< 0.0000	1); l² =			•	+
Test for overall effect: Z = 3.41									
Test for subaroup differences:			lf = 5 (F	< 0.00	001). F	² = 89.4	%		Favours [experimental] Favours [control]

FIG

Forest plot of adjusted standard mean difference in cognitive assessment scores.



Data availability statement

Author contributions


The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

YL, KW, and ZW designed and carried out the study. ZG and CM participated in analyzing and interpretation of the results. YL and KW

wrote the manuscript with other authors' inputs. ZW revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This research was partially funded by grants from Tianjin "project + team" key cultivation program (No. XC202034) and Tianjin Key



Medical Discipline (Specialty) Construction Project (No. TJYXZDXK-009A).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor XG declared a shared parent affiliation with the author KW at the time of review.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnagi.2023.1126183/full#s upplementary-material

					50.5%	
Std_Eff	Coefficient	Std. err.	t	P>[t]	[95% conf.	intervalj
slope	0371452	.0557607	-0.67	0.535	1804827	.1061923
bias	1.965567	.8795454	2.23	0.076	2953768	4.22651

FIGURE 8

Egger's test of publication bias.

References

Areosa Sastre, A., Vernooij, R. W., González-Colaço Harmand, M., and Martínez, G. (2017). Effect of the treatment of type 2 diabetes mellitus on the development of cognitive impairment and dementia. *Cochrane Database Syst. Rev.* 2017:Cd003804. doi: 10.1002/14651858.CD003804.pub2

Biessels, G. J., and Despa, F. (2018). Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. *Nat. Rev. Endocrinol.* 14, 591–604. doi: 10.1038/s41574-018-0048-7

Biessels, G. J., Verhagen, C., Janssen, J., van den Berg, E., Wallenstein, G., Zinman, B., et al. (2021). Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled Carolina-Cognition study. *Diabetologia* 64, 1235–1245. doi: 10.1007/s00125-021-05393-8

Cao, B., Rosenblat, J. D., Brietzke, E., Park, C., Lee, Y., Musial, N., et al. (2018). Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: a systematic review and network meta-analysis. *Diabetes Obes. Metab.* 20, 2467–2471. doi: 10.1111/dom.13373

Cukierman-Yaffe, T., Bosch, J., Diaz, R., Dyal, L., Hancu, N., Hildebrandt, P., et al. (2014). Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. *Lancet Diabetes Endocrinol.* 2, 562–572. doi: 10.1016/s2213-8587(14)70062-2

Cukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L. E., Lakshmanan, M., et al. (2020). Effect of dulaglutide on cognitive impairment in type 2

diabetes: an exploratory analysis of the REWIND trial. *Lancet Neurol.* 19, 582–590. doi: 10.1016/s1474-4422(20)30173-3

Cummings, J., Schwartz, G. G., Nicholls, S. J., Khan, A., Halliday, C., Toth, P. P., et al. (2021). Cognitive effects of the BET protein inhibitor Apabetalone: a Prespecified Montreal cognitive assessment analysis nested in the BETonMACE randomized controlled trial. *J. Alzheimers Dis.* 83, 1703–1715. doi: 10.3233/jad-210570

de la Monte, S. M., and Wands, J. R. (2008). Alzheimer's disease is type 3 diabetesevidence reviewed. J. Diabetes Sci. Technol. 2, 1101–1113. doi: 10.1177/193229680800200619

Duarte, A. I., Moreira, P. I., and Oliveira, C. R. (2012). Insulin in central nervous system: more than just a peripheral hormone. J. Aging Res. 2012:384017. doi: 10.1155/2012/384017

Furie, K. L., Viscoli, C. M., Gorman, M., Ford, G. A., Young, L. H., Inzucchi, S. E., et al. (2018). Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial. *J. Neurol. Neurosurg. Psychiatry* 89, 21–27. doi: 10.1136/jnnp-2017-316361

Ganguli, M., Beer, J. C., Zmuda, J. M., Ryan, C. M., Sullivan, K. J., Chang, C. H., et al. (2020). Aging, diabetes, obesity, and cognitive decline: a population-based study. *J. Am. Geriatr. Soc.* 68, 991–998. doi: 10.1111/jgs.16321

Gerstein, H. C., Hart, R., Colhoun, H. M., Diaz, R., Lakshmanan, M., Botros, F. T., et al. (2020). The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. *Lancet Diabetes Endocrinol.* 8, 106–114. doi: 10.1016/s2213-8587(19)30423-1

Ghetti, S., Kuppermann, N., Rewers, A., Myers, S. R., Schunk, J. E., Stoner, M. J., et al. (2020). Cognitive function following diabetic ketoacidosis in children with new-onset or previously diagnosed type 1 diabetes. *Diabetes Care* 43, 2768–2775. doi: 10.2337/dc20-0187

Gudala, K., Bansal, D., Schifano, F., and Bhansali, A. (2013). Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. *J. Diabetes Investig.* 4, 640–650. doi: 10.1111/jdi.12087

Guo, M., Mi, J., Jiang, Q. M., Xu, J. M., Tang, Y. Y., Tian, G., et al. (2014). Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. *Clin. Exp. Pharmacol. Physiol.* 41, 650–656. doi: 10.1111/1440-1681.12265

Hanyu, H., Sato, T., Kiuchi, A., Sakurai, H., and Iwamoto, T. (2009). Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. *J. Am. Geriatr. Soc.* 57, 177–179. doi: 10.1111/j.1532-5415.2009.02067.x

He, J. T., Zhao, X., Xu, L., and Mao, C. Y. (2020). Vascular risk factors and Alzheimer's disease: blood-brain barrier disruption, metabolic syndromes, and molecular links. *J. Alzheimers Dis.* 73, 39–58. doi: 10.3233/jad-190764

Isik, A. T., Soysal, P., Yay, A., and Usarel, C. (2017). The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer's disease. *Diabetes Res. Clin. Pract.* 123, 192–198. doi: 10.1016/j.diabres.2016.12.010

Jash, K., Gondaliya, P., Kirave, P., Kulkarni, B., Sunkaria, A., and Kalia, K. (2020). Cognitive dysfunction: a growing link between diabetes and Alzheimer's disease. *Drug Dev. Res.* 81, 144–164. doi: 10.1002/ddr.21579

Köbe, T., Witte, A. V., Schnelle, A., Tesky, V. A., Pantel, J., Schuchardt, J. P., et al. (2017). Impact of resveratrol on glucose control, hippocampal structure and connectivity, and memory performance in patients with mild cognitive impairment. *Front. Neurosci.* 11:105. doi: 10.3389/fnins.2017.00105

Lacy, M. E., Gilsanz, P., Eng, C., Beeri, M. S., Karter, A. J., and Whitmer, R. A. (2020). Severe hypoglycemia and cognitive function in older adults with type 1 diabetes: the study of longevity in diabetes (SOLID). *Diabetes Care* 43, 541–548. doi: 10.2337/dc19-0906

Lester-Coll, N., Rivera, E. J., Soscia, S. J., Doiron, K., Wands, J. R., and de la Monte, S. M. (2006). Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. *J. Alzheimers Dis.* 9, 13–33. doi: 10.3233/jad-2006-9102

Li, Q., Jia, M., Yan, Z., Li, Q., Sun, F., He, C., et al. (2021). Activation of glucagon-like Peptide-1 receptor ameliorates cognitive decline in type 2 diabetes mellitus through a metabolism-independent pathway. J. Am. Heart Assoc. 10:e020734. doi: 10.1161/jaha.120.020734

Lin, Y., Wang, K., Ma, C., Wang, X., Gong, Z., Zhang, R., et al. (2018). Evaluation of metformin on cognitive improvement in patients with non-dementia vascular cognitive impairment and abnormal glucose metabolism. *Front. Aging Neurosci.* 10:227. doi: 10.3389/fnagi.2018.00227

McMillan, J. M., Mele, B. S., Hogan, D. B., and Leung, A. A. (2018). Impact of pharmacological treatment of diabetes mellitus on dementia risk: systematic review and meta-analysis. *BMJ Open Diabetes Res. Care* 6:e000563. doi: 10.1136/bmjdrc-2018-000563

Milstein, J. L., and Ferris, H. A. (2021). The brain as an insulin-sensitive metabolic organ. *Mol. Metab.* 52:101234. doi: 10.1016/j.molmet.2021.101234

Moore, E. M., Mander, A. G., Ames, D., Kotowicz, M. A., Carne, R. P., Brodaty, H., et al. (2013). Increased risk of cognitive impairment in patients with diabetes is associated with metformin. *Diabetes Care* 36, 2981–2987. doi: 10.2337/dc13-0229

Morris, J. K., Vidoni, E. D., Mahnken, J. D., Montgomery, R. N., Johnson, D. K., Thyfault, J. P., et al. (2016). Cognitively impaired elderly exhibit insulin resistance and no memory improvement with infused insulin. *Neurobiol. Aging* 39, 19–24. doi: 10.1016/j. neurobiolaging.2015.11.005

Pignalosa, F. C., Desiderio, A., Mirra, P., Nigro, C., Perruolo, G., Ulianich, L., et al. (2021). Diabetes and cognitive impairment: a role for Glucotoxicity and dopaminergic dysfunction. *Int. J. Mol. Sci.* 22:12366. doi: 10.3390/ijms222212366

Plastino, M., Fava, A., Pirritano, D., Cotronei, P., Sacco, N., Sperlì, T., et al. (2010). Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. *J. Neurol. Sci.* 288, 112–116. doi: 10.1016/j.jns.2009.09.022

Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., and Iwamoto, T. (2011). Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. *Neurobiol. Aging* 32, 1626–1633. doi: 10.1016/j.neurobiolaging.2009.10.009

Tahmi, M., Palta, P., and Luchsinger, J. A. (2021). Metabolic syndrome and cognitive function. *Curr. Cardiol. Rep.* 23:180. doi: 10.1007/s11886-021-01615-y

Umegaki, H., Makino, T., Uemura, K., Shimada, H., Hayashi, T., Cheng, X. W., et al. (2017). The associations among insulin resistance, hyperglycemia, physical performance, diabetes mellitus, and cognitive function in relatively healthy older adults with subtle cognitive dysfunction. *Front. Aging Neurosci.* 9:72. doi: 10.3389/fnagi.2017.00072

van Sloten, T. T., Sedaghat, S., Carnethon, M. R., Launer, L. J., and Stehouwer, C. D. A. (2020). Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression. *Lancet Diabetes Endocrinol.* 8, 325–336. doi: 10.1016/ s2213-8587(19)30405-x

Xu, W., Yang, Y., Yuan, G., Zhu, W., Ma, D., and Hu, S. (2015). Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes. *J. Investig. Med.* 63, 267–272. doi: 10.1097/jim.00000000000129

Xue, M., Xu, W., Ou, Y. N., Cao, X. P., Tan, M. S., Tan, L., et al. (2019). Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies. *Ageing Res. Rev.* 55:100944. doi: 10.1016/j. arr.2019.100944